Hengan International Group Co Ltd (HK:1044)
:1044
Want to see HK:1044 full AI Analyst Report?
Top Page
Hengan International Group Co
(1044)
Select Model
Select Model
Rating:60Neutral
Price Target:
HK$23.00
▼(-11.40% Downside)
Action:Downgraded
Date:04/17/26
The score is driven primarily by steady (but low-growth) financial performance with solid cash generation and manageable leverage, supported by a reasonable P/E and high dividend yield. This is partially offset by weak near-term technical momentum (below key moving averages with negative MACD and low RSI).
Positive Factors
Free cash flow generation
Consistent positive operating and free cash flow (~3.2B and ~2.2B in 2025) provides durable internal funding for dividends, capex and working capital. This cash generation supports financial flexibility and resilience in a low-growth consumer staples environment.
Negative Factors
Stagnant to declining revenue trend
Persistent flat or declining top-line reduces operating leverage and constrains long-term growth optionality. Without sustained revenue expansion, the firm must rely on margin recovery or cost cuts to improve returns, limiting upside in 2-6 months.
Read all positive and negative factors
Positive Factors
Negative Factors
Free cash flow generation
Consistent positive operating and free cash flow (~3.2B and ~2.2B in 2025) provides durable internal funding for dividends, capex and working capital. This cash generation supports financial flexibility and resilience in a low-growth consumer staples environment.
Read all positive factors
Hengan International Group Co (1044) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$25.58B
Dividend Yield5.36%
Average Volume (3M)2.04M
Price to Earnings (P/E)8.6
Beta (1Y)0.71
Revenue Growth1.76%
EPS Growth10.34%
CountryHK
Employees24,000
SectorConsumer Defensive
Sector Strength42
IndustryHousehold & Personal Products
Share Statistics
EPS (TTM)2.23
Shares Outstanding1,162,121,000
10 Day Avg. Volume1,895,839
30 Day Avg. Volume2,040,272
Financial Highlights & Ratios
PEG Ratio1.03
Price to Book (P/B)1.31
Price to Sales (P/S)1.24
P/FCF Ratio13.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$23.00Price Target Upside-11.40% Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)2.11
Revenue Forecast (FY)HK$23.27B
Hengan International Group Co Business Overview & Revenue Model
Company Description
Hengan International Group Company Limited functions as an investment holding company, with its primary focus on the manufacturing, distribution, and sale of personal care and hygiene products. Its market reach extends across the People's Republic...
How the Company Makes Money
Hengan makes money mainly by selling fast-moving consumer goods (FMCG) in the personal hygiene and household paper categories. Its core revenue streams come from (1) personal hygiene products—particularly sanitary napkins and diapers (including ba...
Hengan International Group Co Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
58
Neutral
Cash Flow
66
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 23.07B | 22.67B | 23.77B | 22.62B | 20.79B |
| Gross Profit | 7.81B | 7.32B | 8.01B | 7.69B | 7.77B |
| EBITDA | 3.90B | 4.43B | 5.14B | 4.12B | 4.55B |
| Net Income | 2.54B | 2.30B | 2.80B | 1.93B | 3.27B |
Balance Sheet | |||||
| Total Assets | 43.20B | 39.80B | 40.22B | 42.34B | 42.29B |
| Cash, Cash Equivalents and Short-Term Investments | 15.62B | 14.32B | 18.22B | 18.70B | 18.26B |
| Total Debt | 15.77B | 13.11B | 14.27B | 17.07B | 18.26B |
| Total Liabilities | 21.22B | 18.66B | 19.59B | 22.56B | 23.01B |
| Stockholders Equity | 21.76B | 20.92B | 20.40B | 19.52B | 19.04B |
Cash Flow | |||||
| Free Cash Flow | 2.19B | 1.52B | 2.35B | 2.57B | 3.82B |
| Operating Cash Flow | 3.24B | 3.07B | 3.88B | 3.81B | 4.60B |
| Investing Cash Flow | -5.68B | -110.26M | 3.58B | -6.07B | 2.68B |
| Financing Cash Flow | 769.03M | -3.59B | -5.55B | -4.14B | -6.49B |
Hengan International Group Co Technical Analysis
Negative
25.96
Price Trends
25.02
Negative
26.20
Negative
26.24
Negative
Market Momentum
-0.80
Positive
26.52
Positive
8.15
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1044, the sentiment is Negative. The current price of 25.96 is above the 20-day moving average (MA) of 23.86, above the 50-day MA of 25.02, and below the 200-day MA of 26.24, indicating a bearish trend. The MACD of -0.80 indicates Positive momentum. The RSI at 26.52 is Positive, neither overbought nor oversold. The STOCH value of 8.15 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1044.
Hengan International Group Co Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | HK$10.73B | 8.44 | 42.42% | 2.53% | 35.28% | 41.20% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
60 Neutral | HK$25.58B | 8.57 | 11.65% | 5.36% | 1.76% | 10.34% | |
57 Neutral | HK$101.20M | 23.13 | 2.65% | ― | 8.10% | -36.36% | |
51 Neutral | HK$16.85B | -48.87 | -4.30% | 5.00% | -1.71% | 53.04% | |
48 Neutral | HK$920.97M | 86.79 | -12.38% | ― | 52.36% | ― |
* Consumer Defensive Sector Average
HK:1044
Hengan International Group Co
22.04
0.99
4.71%
HK:0157
Natural Beauty Bio-Technology
0.46
-0.08
-14.81%
HK:1338
BaWang International (Group) Holding Limited
0.03
-0.02
-37.25%
HK:2145
Shanghai Chicmax Cosmetics Co., Ltd. Class H
26.96
-51.14
-65.48%
HK:6993
Blue Moon Group Holdings Ltd.
3.03
-0.93
-23.39%
HK:6883
Eternal Beauty Holdings Limited
2.03
-0.08
-3.79%
Hengan International Group Co Corporate Events
Hengan Names CEO Hui Ching Lau as Acting Chairman During Chairman’s Health Leave
Jun 23, 2026
Hengan International Group has appointed chief executive officer and executive director Hui Ching Lau as acting chairman of the board, effective 23 June 2026, to cover the leave of absence of chairman Sze Man Bok due to health reasons. The board e...
Hengan International Updates Board Roles and Committee Structure
Jun 23, 2026
Hengan International Group Company Limited has updated the composition of its board, naming Mr. Sze Man Bok as executive director and chairman, and Mr. Hui Ching Lau as executive director, chief executive officer and acting chairman, alongside sev...
Hengan International Chairman Takes Health-Related Leave as Board Affirms Stable Operations
Jun 9, 2026
Hengan International Group Company Limited announced that its chairman and executive director, Mr. Sze Man Bok, has taken a temporary leave of absence from his duties due to personal health reasons. The board emphasized that the group’s oper...
Hengan Shareholders Approve All AGM Resolutions and Renew Capital Mandates
May 18, 2026
Hengan International Group Co reported that all resolutions at its 18 May 2026 annual general meeting were approved by shareholders via poll, including receipt of the 2025 audited accounts, declaration of a final dividend, re-election of key board...
Hengan International Updates Board Composition and Governance Committees
May 18, 2026
Hengan International Group Company Limited has updated its board composition, confirming Sze Man Bok as executive director and chairman and Hui Ching Lau as executive director and chief executive officer, alongside other executive, non-executive, ...
Hengan Corrects Earnings Per Share Unit in 2025 Annual Report
Apr 28, 2026
Hengan International Group Company Limited has issued a clarification regarding its 2025 annual report, noting that the presentation unit for earnings per share on page 5 was misstated due to a clerical error. The company confirmed that the correc...
Hengan International Revamps Company Secretary and Governance Roles
Apr 27, 2026
Hengan International Group Company Limited announced a change in key corporate governance roles, with company secretary and authorised representative Mr. Pang Yiu Chi Edwin resigning from those posts effective 27 April 2026, while remaining Financ...
Hengan International Clarifies AGM Date After Clerical Error in Circular
Apr 15, 2026
Hengan International Group Company Limited has issued a clarification regarding its previously distributed circular and notice of annual general meeting to shareholders. The company, whose shares trade on the Hong Kong Stock Exchange, remains focu...
Hengan Sets 2026 AGM to Vote on Dividend, Director Slate and Share Buyback Mandate
Apr 15, 2026
Hengan International Group Company Limited has called its annual general meeting for 18 May 2026 in Hong Kong, where shareholders will review the audited consolidated accounts and reports for the year ended 31 December 2025 and vote on a proposed ...
Hengan International Reassigns Veteran Executive Xu Wenmo to Non-Executive Board Role
Apr 15, 2026
Hengan International Group has proposed the re-designation of Xu Wenmo from executive director to non-executive director, effective after his expected re-election at the 18 May 2026 annual general meeting. Xu, currently vice president overseeing l...
Hengan International Outlines Board and Committee Structure
Mar 31, 2026
Hengan International Group Company Limited has announced the current composition of its board of directors, led by executive director and chairman Mr. Sze Man Bok and executive director and chief executive officer Mr. Hui Ching Lau, alongside seve...
Hengan International Announces CFO and Company Secretary Transition Effective April 2026
Mar 31, 2026
Hengan International Group has announced that Mr. Li Wai Leung will resign as executive director, chief financial officer, company secretary, and authorised representative with effect from 1 April 2026, to pursue other career opportunities. The bo...
Hengan Raises RMB2 Billion in Third Tranche of Super Short-Term Commercial Papers
Mar 31, 2026
Hengan International Group Company Limited has completed the issuance of the third tranche of its super short-term commercial papers, raising RMB2 billion with a 1.68% annual coupon and a 183-day term. This issue forms part of a broader RMB7.5 bil...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.